



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

**0 207 589
A1**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 86302425.3

(22) Date of filing: 02.04.86

(51) Int. Cl. 4: **C12N 15/00**, **C12N 9/68**,
C07H 21/04, **C12N 5/00**,
A61K 37/54, **C12P 21/00**

The title of the invention has been amended
(Guidelines for Examination in the EPO, A-III,
7.3).

(30) Priority: 03.04.85 GB 8508972
27.02.86 GB 8604852

(36) Date of publication of application:
07.01.87 Bulletin 87/02

(64) Designated Contracting States:
BE CH DE FR GB IT LI LU NL SE

(71) Applicant: **BEECHAM GROUP PLC**
Beecham House Great West Road
Brentford Middlesex TW8 9BD(GB)

(72) Inventor: **Robinson, Jeffery Hugh**
3 Hillcrest Close Epsom
Surrey KT18 6JY(GB)
Inventor: **Browne, Michael Joseph**
7 Delaporte Close Epsom
Surrey KT17 1AF(GB)
Inventor: **Tyrrell, Arthur William Russell**
"White Friars" 38 St. Albans Road
Reigate Surrey RH2 9LN(GB)

(74) Representative: **Valentine, Jill Barbara et al**
Beecham Pharmaceuticals Patents & Trade
Marks Dept. Great Burgh Yew Tree Bottom
Road
Epsom Surrey KT18 6XQ(GB)

(54) **Fibrinolytic enzyme.**

(57) A fibrinolytically active tissue-type plasminogen
activator which has been modified in the region of
the growth factor domain.

EP 0 207 589 A1

N vel Compounds

The present invention relates to a modified fibrinolytic enzyme in particular modified tissue-type plasminogen activator, its preparation, pharmaceutical compositions containing it and its use in the treatment of thrombotic disease.

The sequence of amino acids making up the enzyme tissue-type plasminogen activator (t-PA) and the nucleotide sequence for the cDNA which codes for t-PA are known (see Pennica et al, 1983; Nature, 301, 214). Tissue-type plasminogen activator is known to have fibrinolytic activity but tends to be rapidly cleared from the bloodstream.

It has been shown (Bányai, L. *et al.*, 1983; FEBS Lett., 163, 37) that a part of the t-PA enzyme shows structural homology with human and murine epidermal growth factors. This region from amino acid residues 44 to 91 has been termed the "growth factor domain". The genetic information which codes for the major part of this domain, residues 51 to 86 inclusive, and partially codes for residues 50 and 87, lies on a single exon (Ny, T. *et al.*, 1984; Proc. Nat. Acad. Sci. U.S.A., 81, 5355).

The applicants have now identified modified forms of the t-PA enzyme which retain fibrinolytic activity.

According to the present invention there is provided a fibrinolytically active tissue-type plasminogen activator which has been modified in the region of the growth factor domain.

Suitable modifications may include removal or deletion of certain amino acid residues, or replacement of one or more amino acid residues with different amino acid residues.

In a preferred aspect, the modification comprises the deletion of all or part of the growth factor domain.

In another preferred aspect, the t-PA is modified in the region from amino acid residues 51 to 87 inclusive, in particular by deletion of that region.

As used herein, the term tissue-type plasminogen activator denotes a plasminogen activator of the group having the immunological properties defined for t-PA at the XXVIII Meeting of the International Committee on Thrombosis and Haemostasis, Bergamo, Italy, 27 July 1982.

The amino acid sequence of various forms of t-PA are known. The abovementioned Nature 1983 reference discloses the sequence for the L-chain and the mature S-chain forms of t-PA, also discussed by Vehar *et al.*, Biotechnology, 1984, 2, 1051-7 in which the processing of initially formed t-PA by removal of a pro-sequence to give the S-chain form is reported. Pohl *et al.*, FEBS letters, 1984, Vol. 168 No.1, 29-32, refers to the N-terminal multiplicity of t-PA and discloses the U-chain form.

The numbering system for the amino acid sequence of t-PA used herein is that described in the Nature 1983 reference for mature (S-chain) t-PA in which the N-terminal serine is numbered 1. By this system, L-chain t-PA has an N-terminal glycine residue at position -3 and U-chain t-PA has an N-terminal valine at position 4. It is understood that the tissue-type plasminogen activator modified in accordance with the present invention encompasses all such variant forms.

The modified t-PA of the invention may be derivatised to provide pharmaceutically useful conjugates analogous to known t-PA-containing conjugates, for example:

(a) an enzyme-protein conjugate as disclosed in EP-A-O 155 388, in which the catalytic site on the enzyme which is responsible for fibrinolytic activity is blocked by a human protein attached thereto by way of a reversible linking group;

(b) an enzyme-protein conjugate as disclosed in EP-A-O 152,736, comprising at least one optionally blocked fibrinolytic enzyme linked by way of a site other than the catalytic site responsible for fibrinolytic activity to at least one human protein;

(c) a protein-polymer conjugate as disclosed in co-pending European application no. 85308533.0 comprising a pharmaceutically useful protein linked to at least one water soluble polymer by means of a reversible linking group; or

(d) an enzyme conjugate as disclosed in co-pending European application no. 85308534.8 comprising a plurality of fibrinolytic enzymes linked together through the active centres thereof by means of a removable blocking group.

The modified t-PA of the invention may take the place of t-PA as the enzyme or (human) protein component, as appropriate, of any of the conjugates described above.

The modified t-PA of the invention or conjugate thereof can be further derivatised such that any catalytic site essential for fibrinolytic activity is optionally blocked by a removable blocking group.

The above mentioned derivatives of the modified t-PA may be used in any of the methods and compositions described hereinafter for the modified t-PA itself.

As used herein the expression 'removable blocking group' includes groups which are removable by hydrolysis at a rate such that the pseudo-first order rate constant for hydrolysis is in the range of 10^{-4} sec^{-1} to 10^{-2} sec^{-1} in isotonic aqueous media at pH 7.4 at 37°C.

Such blocking groups are described in European Patent No.0009879 and include acyl groups such as optionally substituted benzoyl or optionally substituted acryloyl.

Suitable optional substituents for benzoyl blocking groups include halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkanoyloxy, C₁₋₆ alkanoylamino, amino or p-guanidino.

Suitable optional substituents for acryloyl blocking groups include C₁₋₆ alkyl, furyl, phenyl or C₁₋₆ alkylphenyl.

In a further aspect, the invention provides a process for preparing modified tissue-type plasminogen activator according to the invention which process comprises expressing DNA encoding said modified tissue-type plasminogen activator in a recombinant host cell and recovering the modified tissue-type plasminogen activator product.

The modification of the t-PA can therefore be carried out by conventional genetic engineering techniques in which the cDNA which codes for t-PA is modified and the modified cDNA expressed in a prokaryote or eukaryote host.

The DNA polymer comprising a nucleotide sequence that encodes the modified t-PA also forms part of the invention.

The process of the invention may be performed by conventional recombinant techniques such as described in Maniatis *et al.*, Molecular Cloning -A Laboratory Manual; Cold Spring Harbor, 1982.

In particular, the process may comprise the steps of:

i) preparing a replicable expression vector capable, in a host cell, of expressing a DNA polymer comprising a nucleotide sequence that encodes said modified tissue-type plasminogen activator;

ii) transforming a host cell with said vector;

iii) culturing said transformed host cell under conditions permitting expression of said DNA polymer to produce said modified tissue-type plasminogen activator; and

iv) recovering said modified tissue-type plasminogen activator.

The invention also provides a process for preparing the DNA polymer by the condensation of appropriate mono-, di- or oligomeric nucleotide units.

The preparation may be carried out chemically, enzymatically, or by a combination of the two methods, *in vitro* or *in vivo* as appropriate. Thus, the DNA polymer may be prepared by the enzymatic ligation of chemically synthesised DNA fragments, by conventional methods such as those described by D. M. Roberts *et al.* in Biochemistry 1985, 24, 5090-5098. The chemical synthesis may be performed generally as described hereinafter for the synthesis of an oligodeoxyribonucleotide. En-

zymatic polymerisation of DNA may be carried out *in vitro* using a DNA polymerase such as DNA polymerase I (Klenow fragment) in an appropriate buffer containing the nucleoside triphosphates dATP, dCTP, dGTP and dTTP as required at a temperature of 10°-37°C, generally in a volume of 50µl or less. Enzymatic ligation of DNA fragments may be carried out using a DNA ligase such as T4 DNA ligase in an appropriate buffer at a temperature of 4°C to ambient, generally in a volume of 50µl or less. DNA polymer which encodes the modified t-PA may be prepared by site-directed mutagenesis of the cDNA which codes for tissue-type plasminogen activator, by conventional methods such as those described by G. Winter *et al.* in Nature 1982, 299, 756-758 or by Zoller and Smith 1982; Nucl. Acids Res., 10, 6487-6500, or deletion mutagenesis such as described by Chan and Smith in Nucl. Acids Res., 1984, 12, 2407-2419 or by G. Winter *et al.* in Biochem. Soc. Trans., 1984, 12, 224-225. Expression of the modified cDNA can be carried out by conventional methods.

The above described mutagenesis processes involve the use of oligodeoxyribonucleotides which can be designed according to the changes in the cDNA sequence coding for amino acids 44 to 91 inclusive required.

The oligodeoxyribonucleotides which may be used in such processes also form part of the invention.

The invention also provides a process for preparing an oligodeoxyribonucleotide of the invention, which process comprises the deprotection of a second oligodeoxyribonucleotide having the same sequence of bases as said oligodeoxyribonucleotide and in which all free hydroxy and amino groups are protected.

The oligodeoxyribonucleotides used in the process can be prepared by conventional phosphotriester, phosphite or phosphoramidite chemistry, using solid phase techniques such as those described in 'Chemical and Enzymatic Synthesis of Gene Fragments -A Laboratory Manual, (ed. H.G. Gassen and A. Lang), Verlag Chemie, Weinheim (1982), or in other scientific publications, for example M.J. Gait, H.W.D. Matthes, M. Singh, B.S. Sproat, and R.C. Titmas, Nucleic Acids Research, 1982, 10, 6243; B.S. Sproat and W. Bannwarth, Tetrahedron Letters, 1983, 24, 5771; M.D. Matteucci and M.H. Caruthers, Tetrahedron Letters, 1980, 21, 719; M.D. Matteucci and M.H. Caruthers, Journal of the American Chemical Society, 1981, 103, 3185; S.P. Adams *et al.*, Journal of the American Chemical Society, 1983, 105, 661; N.D. Sinha, J. Biernat, J. McMannus, and H. Koester, Nucleic Acids Research, 1984, 12, 4539; and H.W.D. Matthes *et al.*, EMBO Journal, 1984, 3, 801.

Solid supports which may be employed include conventional supports known in the art, for example kieselguhr-polydimethylacrylamide, silica, controlled-pore glass, or cellulose paper discs. The base at the 3'-end of the oligodeoxyribonucleotide to be prepared is attached, via a spacer group connected to the 3'-oxygen of the terminal 2'-deoxyribose unit, to the solid support and assembly of the oligodeoxyribonucleotide (in a protected form) is carried out in the 3' → 5'-direction by cycles of synthesis, the required operations being performed either manually or by an automated instrument.

At the end of the synthesis, the protected oligodeoxyribonucleotide may be cleaved from the solid support either before, after, or at the same time as other deprotection steps that are carried out once the desired sequence of bases has been assembled, as described hereinbelow. Conveniently the oligodeoxyribonucleotide is removed from the solid support by treatment with a basic reagent such as aqueous ammonia at ambient or slightly elevated temperature, or with 1,1,3,3-tetramethylguanidinium-*syn*-2-nitrobenzaldoximate or similar reagents in aqueous dioxan at ambient or slightly elevated temperature.

Alternatively, the preparation may be carried out conventionally by phosphotriester chemistry in solution as described, for example, by C.B. Reese, Tetrahedron, 1978, 34, 3143-3179.

The required sequence of nucleotide bases in the oligodeoxyribonucleotide may be built up conventionally, for example as described in the aforementioned publications, by the condensation of appropriate mono-, di- or oligomeric nucleotide units in the presence of a suitable condensing agent such as 1-(mesitylenesulphonyl)-3-nitro-1,2,4-triazole in a solvent such as pyridine at ambient or slightly elevated temperature (when phosphotriester chemistry is employed) or by a condensing agent such as tetrazole in acetonitrile at ambient temperature (when phosphite or phosphoramidite chemistry is used). Optionally a 'capping' step is introduced after each condensation step to inactivate any unreacted starting material containing a free 5'-hydroxy group. Such a capping step may suitably be carried out by an acylating agent such as acetic anhydride in 2,6-lutidine and 4-*N,N*-dimethylamino-pyridine in tetrahydrofuran at ambient temperature.

When phosphite or phosphoramidite chemistry is employed, the phosphorus (III) atom in the phosphite-triester internucleotide linkage created in each condensation step is oxidised, giving the corresponding phosphotriester linkage, before a further condensation step is carried out. Such oxidations may be carried out using a convenient oxidising agent, for example iodine in aqueous

tetrahydrofuran in the presence of a base such as lutidine. The oxidation step is conveniently carried out after the optional 'capping' step as hereinbefore described.

During the synthesis of the oligodeoxyribonucleotide, the hydroxy groups in each of the internucleotide phosphodiester bridges may be protected by an aryl group or alkyl group conventionally employed for the purpose, for example 2- or 4-chlorophenyl, methyl, or 2-cyanoethyl, to prevent branching of the molecule. The aryl protecting groups are removed at the end of the synthesis by treatment with an agent conventionally employed for the purpose, for example 1,1,3,3-tetramethylguanidinium-*syn*-2-nitrobenzaldoximate in an aqueous solvent such as aqueous dioxan at ambient temperature. The methyl groups may be removed at the end of the synthesis by treatment with triethylammonium thiophenolate in dioxan at ambient temperature. The 2-cyanoethyl groups may be removed at the end of the synthesis with a basic reagent such as triethylamine or *tert*-butylamine in pyridine at ambient temperature, or alternatively by treatment with concentrated aqueous ammonia at about 50°C (a step which simultaneously and advantageously removes the protecting groups present on the A, C and G bases as described hereinbelow).

The amino groups present in the A, C and G bases are protected by base-labile protecting groups, such as benzoyl for A and C, and isobutyryl for G. Such groups may be removed by treatment with basic reagents, for example ammonia at ambient or slightly elevated temperature, for example 50°C. The 5'-hydroxy group of the terminal ribose moiety is protected by an acid-labile group such as trityl, 4,4'-dimethoxytrityl or pbxyl - (9-phenyl-9-xanthyl), which is removed before each condensation step and at the end of synthesis. Such groups may be removed by treatment with an acidic reagent such as di- or trichloroacetic acid in an anhydrous solvent such as dichloromethane or chloroform, at ambient temperature.

The expression of the DNA polymer encoding the modified t-PA in a recombinant host cell may be carried out by means of a replicable expression vector capable, in the host cell, of expressing the DNA polymer. The expression vector is novel and also forms part of the invention.

The replicable expression vector may be prepared in accordance with the invention, by cleaving a vector compatible with the host cell to provide a linear DNA segment having an intact replicon, and combining said linear segment with the DNA polymer encoding the modified t-PA under ligating conditions.

The choice of vector will be determined in part by the host cell, which may be prokaryotic or eukaryotic. Suitable vectors include plasmids, bacteriophages and cosmids.

The preparation of the replicable expression vector may be carried out conventionally with appropriate enzymes for restriction, polymerisation and ligation of the DNA, by procedures described in, for example, Maniatis *et al* cited above. Polymerisation and ligation may be performed as described above for the preparation of the DNA polymer. Digestion with restriction enzymes may be performed in an appropriate buffer at a temperature of 20°-70°C, generally in a volume of 50µl or less with 0.1-10µg DNA.

The recombinant host cell is prepared, in accordance with the invention, by transforming a host cell with a replicable expression vector of the invention under transforming conditions. Suitable transforming conditions are conventional and are described in, for example, Maniatis *et al* cited above, or "DNA Cloning" Vol. II, D.M. Glover ed., IRL Press Ltd, 1985.

The choice of transforming conditions is determined by the host cell. Thus, a bacterial host such as *E. coli* may be treated with a solution of CaCl₂ - (Cohen *et al*, Proc. Nat. Acad. Sci., 1973, 69, 2110) or with a solution comprising a mixture of RbCl, MnCl₂, potassium acetate and glycerol, and then with 3-[N-morpholino]propane-sulphonic acid, RbCl and glycerol. Mammalian cells in culture may be transformed by calcium co-precipitation of the vector DNA onto the cells. The invention also extends to a host cell transformed with a replicable expression vector of the invention.

Culturing the transformed host cell under conditions permitting expression of the DNA polymer is carried out conventionally, as described in, for example, Maniatis *et al* and "DNA Cloning" cited above. Thus, preferably the cell is supplied with nutrient and cultured at a temperature below 45°C.

The modified t-PA expression product is recovered by conventional methods according to the host cell. Thus, where the host cell is bacterial, such as *E. coli* it may be lysed physically, chemically or enzymatically and the protein product isolated from the resulting lysate. Where the host cell is mammalian, the product may generally be isolated from the nutrient medium. The DNA polymer may be assembled into vectors designed for isolation of stable transformed mammalian cell lines expressing the modified t-PA; e.g. bovine papillomavirus vectors (DNA cloning Vol.II D.M. Glover Ed. IRL Press 1985; Kaufman, R.J. *et al*, Molecular

and Cellular Biology 5, 1750-1759, 1985; Pavlakis G.N. and Hamer, D.H., Proceedings of the National Academy of Sciences, (USA) 80, 397-401, 1983; Goeddel, D.V. *et al*, European Patent Application No. 0093619, 1983).

It will be appreciated that, depending upon the host cell, the modified t-PA prepared in accordance with the invention may be glycosylated to varying degrees. Furthermore, as observed by Pohl *et al*, Biochemistry, 1984, 23, 3701-3707, varying degrees of glycosylation may also be found in unmodified, naturally occurring t-PA. The modified t-PA of the invention is understood to include such glycosylated variations.

In a preferred embodiment, a modified tissue-type plasminogen activator enzyme is prepared by a process which comprises effecting a deletion mutagenesis upon the cDNA which codes for tissue-type plasminogen activator using an oligodeoxyribonucleotide comprising a nucleotide sequence which is complementary or corresponds to a region of the t-PA cDNA extending 5' from nucleotide 339 inclusive, said sequence being joined directly to a nucleotide sequence which is complementary or corresponds to a region extending 3' from nucleotide 451 inclusive of t-PA cDNA and expressing the modified cDNA in a prokaryote or eukaryote host.

The oligodeoxyribonucleotide employed in the preferred embodiment is suitably at least 16 nucleotides in length, preferably at least 25 nucleotides in length. Suitably it contains at least 8 and preferably at least 12 nucleotides which are complementary to nucleotides on each side of the deletion region.

A preferred oligodeoxyribonucleotide is of sequence (I).

5'd(CGTGGCCCTGGTACTTTTGACAGGC)3' (I)

The oligodeoxyribonucleotide of sequence (I) is novel and as such forms part of the invention.

The 12 bases at the 5' end of the oligodeoxyribonucleotide (I) are complementary to t-PA cDNA nucleotides 462-451 inclusive and the 13 bases at the 3' end of the oligodeoxyribonucleotide (I) are complementary to the t-PA cDNA nucleotides 339-327 inclusive.

The oligodeoxyribonucleotide of sequence (I) can be used to delete the portion of cDNA which codes for amino acids 51 to 87 inclusive of t-PA. It is believed that the cDNA obtained following mutagenesis is similar to that of Pennica *et al*, 1983, Nature, 301, 214 with the following new nucleotide sequence:-

55

5' - G CCT GTC AAA AGT ACC AGG GCC ACG 3'

position 327 339 451 462

The t-PA obtained by expression of this cDNA is expected to have a similar amino acid sequence to that described in Pennica *et al.*, except for the following alteration:

position 47 50 88 91
-pro-val-lys-ser-thr-arg-ala-thr-

The modified t-PA of the invention comprises the B-chain of native t-PA linked to t-PA A-chain modified in the region of the growth factor domain. This modified t-PA A-chain may be employed as one chain of a fibrinolytically active hybrid protein such as disclosed in EP-0155387. The modified t-PA A-chain, DNA encoding the modified t-PA A-chain and a hybrid protein comprising the modified t-PA A-chain linked to the B-chain of a fibrinolytically active protease, the catalytic site of which is optionally blocked by a removable blocking group, all form part of the invention. The hybrid protein may be used in any of the methods and compositions described hereinafter for the modified t-PA itself.

The modified t-PA of the invention is suitably administered in the form of a pharmaceutical composition.

Accordingly the present invention also provides a pharmaceutical composition comprising modified t-PA of the invention in combination with a pharmaceutically acceptable carrier.

The compositions according to the invention may be formulated in accordance with routine procedures as pharmaceutical compositions adapted for intravenous administration to human beings.

Typically compositions for intravenous administration are solutions of the sterile enzyme in sterile isotonic aqueous buffer. Where necessary the composition may also include a solubilising agent to keep the modified t-PA in solution and a local anaesthetic such as lignocaine to ease pain at the site of injection. Generally, the modified t-PA will be supplied in unit dosage form for example as a dry powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of protein in activity units. Where the modified t-PA includes a removable blocking group an indication of the time within which the free protein will be liberated may be given. Where the protein is to be administered by infusion, it will be dispensed with an infusion bottle

containing sterile pharmaceutical grade 'Water for Injection' or saline. Where the protein is to be administered by injection, it is dispensed with an ampoule of sterile water for injection or saline. The injectable or infusable composition will be made up by mixing the ingredients prior to administration. The quantity of material administered will depend upon the amount of fibrinolysis required and the speed with which it is required, the seriousness of the thromboembolic condition and position and size of the clot. The precise dose to be employed and mode of administration must per force in view of the nature of the complaint be decided according to the circumstances by the physician supervising treatment. However, in general, a patient being treated for a mature thrombus will generally receive a daily dose of from 0.01 to 10 mg/kg of body weight either by injection in for example up to five doses or by infusion.

Within the above indicated dosage range, no adverse toxicological effects are indicated with the compounds of the invention.

Accordingly, in a further aspect of the invention there is provided a method of treating thrombotic diseases, which comprises administering to the sufferer an effective non-toxic amount of modified t-PA of the invention.

The invention also provides a modified t-PA of the invention for use as an active therapeutic substance and, in particular, for use in the treatment of thrombotic diseases.

The following Examples illustrate the invention.

Example 1

5'd(CGTGGCCCTGGTACTTTTGACAGGC)3'

The above mentioned 25-mer was prepared by the solid phase phosphotriester method on a polydimethylacrylamide-kieselguhr support using dimer building blocks following the standard procedure described in 'Chemical and Enzymatic Synthesis of Gene Fragments -A Laboratory Manual', Chapter 1, Verlag Chemie, Weinheim (1982).

The 25-mer was purified by ion-exchange HPLC on a PARTISIL 10-SAX column eluted at 2ml/min with 0.001 M and 0.3 M KH_2PO_4 , pH 6.3, in 6:4 formamide-water (solvents A and B respectively), using a gradient of 0-100% B over 50 min at room temperature. Detection was at 270nm. In preparative runs, the peak eluting after 53.7 min. was collected. This was followed by reversed phase HPLC on the partially purified 25-mer on a μ -BONDAPAK C-18 column eluted at 2ml/min with 0.1 M ammonium acetate (solvent A) and 0.1 M ammonium acetate-acetonitrile (2:8 v/v, solvent B), using 92% A isocratically for 4 minutes, followed by a gradient of 92-70% A over 41 minutes at room temperature. Detection was at 270 nm. In preparative runs, the material with a retention time of 15.8 min. was collected. This material was purified by preparative gel electrophoresis using standard methodology as described in the above reference.

Sequence verification was carried out by the method of Maxam and Gilbert (see A.M. Maxam and W. Gilbert, 'Sequencing End-Labelled DNA with Base-Specific Chemical Cleavages' in Methods in Enzymology, ed. L. Grossman and K. Moldave, Academic Press Inc. (London) Ltd. (1980), Vol. 65, p.p. 499-580).

The length of the oligonucleotide was verified by a sizing experiment in which the electrophoretic mobility of the oligonucleotide was compared with that of oligo (dT) fragments contained in a commercially available oligo (dT) ladder.

Methods used for Examples 2 to 4

DNA cleavage

In general the cleavage of about 1 μ g of plasmid DNA or DNA fragments was effected using about 5 units of a restriction enzyme (or enzymes) in about 20 μ l of an appropriate buffer solution.

Generation of blunt ends: If blunt ends were required they were produced by treating the DNA preparation with DNA Polymerase I, Klenow fragment (Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory 1982).

Addition of 5' phosphate groups to oligonucleotides: Addition of either labelled or unlabelled phosphate groups to oligonucleotides was carried out as described (Maxam and Gilbert, Methods in Enzymology Vol.65 p499-560 Ed. Grossman and Moldave publisher Academic Press 1980).

Ligation of DNA Fragments: Ligation reactions were carried out as described (Maniatis *et al* Molecular Cloning -A Laboratory Manual, Cold Spring Harbor Laboratory 1982).

Transformation of M13 DNA into bacterial cells was carried out using treatment with calcium chloride (Cohen *et al* 1973, P.N.A.S. 69, 2110).

Transformation of plasmid DNA into *E. coli* HB101 cells was as described by Hanahan (DNA Cloning Vol I Chapter 6, D.M. Glover ed. IRL Press, 1985) in Protocol 3 except that incubation with RFI was for 5 minutes.

Isolation of t-PA cDNA clones

RNA was isolated from the TRBM6 cell line - (Browne *et al* 1985, Thrombosis and Haemostasis; 54; 422-424) using hot phenol/SDS extraction - (M.R.D. Scott, 1982, Ph.D. Thesis, University of London) and messenger RNA purified using oligo dT cellulose chromatography. A TRBM6 cDNA library was established by synthesizing double-stranded cDNA using this messenger RNA essentially as described by M.R.D. Scott (Ph.D. Thesis 1982, University of London). This cDNA preparation was digested with BglII, size fractionated on a Biogel A150 column and ligated into a pAT153 vector which had been modified by introduction of a BglII linker at the NruI site; the resultant DNA clone was propagated in *E. coli* K12 DH1 cells. A t-PA-specific oligonucleotide probe (Browne *et al*, 1985; Gene 33, 279-284) was used to identify a t-PA cDNA clone in the cDNA library, this clone is known as pTR108, and carries a 2kb BglII fragment encoding the mature t-PA protein (Pennica *et al*, 1983, Nature, 301, 214-221).

A further cDNA clone λ TR10, was isolated from a second TRBM6 cDNA library. The cDNA library was constructed using the λ gt10 vector as described in 'DNA Cloning' Volume I, Chapters 2 and 3 (Ed. D.M. Glover (IRL Press, 1985)). The library was screened using appropriate t-PA specific oligonucleotide and plasmid probes using methods described previously (Browne *et al*, 1985, Gene, 33, 279-284). Clone λ TR10 isolated from this library carries additional DNA 5' to that in pTR108, corresponding to the prepro-coding region and part of the 5' untranslated region (Pennica *et al*, 1983, Nature, 301, 214-221).

Growth of M13 single strand DNA: A single M13 phage plaque was picked into a 1:100 dilution in 2YT (1.6% Bactotryptone, 1% Yeast extract, 1% NaCl) of a fresh overnight culture of *E. coli* strain BMH 71-18 (Gronenborn *et al.*, 1976, Mol. Gen. Genet. 148, 243-250). The culture was grown at 37°C with shaking for 5-6 hours. The bacteria were pelleted and the supernatant retained. To this was added 200µl of 2.5M NaCl, 20% PEG6000 and the mixture was incubated at room temperature for 15 minutes. The mixture was centrifuged for 5 minutes in an Eppendorf microfuge and the resulting phage pellet was resuspended in 100µl of 10mM Tris pH 7.9, 0.1mM EDTA. After phenol extraction the phage DNA was precipitated with ethanol. The DNA pellet was washed with 70% ethanol, air dried and resuspended in 30µl of 10mM Tris pH 7.9, 0.1mM EDTA.

Growth of double stranded M13 DNA: A single M13 phage plaque was picked into 1ml of 2YT and grown with shaking at 37°C for 6 hours. The bacteria were pelleted and the supernatant containing M13 phage retained. Meanwhile a one litre 1:100 dilution of an overnight culture of *E. coli* strain BMH 71-18 was grown at 37°C with shaking for 2 hours. 500µl of the M13 phage supernatant was added and the culture was shaken at 37°C for a further 4 hours. Preparation of double stranded DNA was carried out as described by Maniatis *et al.* (Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, 1982).

Site directed mutagenesis: The site-directed mutagenesis reactions were carried out essentially as described in the University of Leicester Gene Cloning and Analysis Course Manual (University of Leicester, U.K. 1985).

The following double priming mixture was set up in a total volume of 5.8µl: 0.2pmoles template DNA (mTR 30 single stranded form, see Example 2); 0.825pmoles kinased mutagenic primer (as described above); 0.375 pmoles kinased M13 specific primer (Collaborative Research Inc., Product No. 20205); 0.6µl 10⁻⁵ seq. buffer (0.1M Tris-Cl pH 7.5, 0.05M MgCl₂). The mixture was heated in an Eppendorf tube at 58°C for 6 minutes and then allowed to cool to room temperature for at least 15 minutes. To the priming mixture was added 8µl of the following mixture: 1µl of 10mM solution of dATP, dGTP, dCTP, dTTP, (4µl total); 2µl 10mM rATP; 2µl 10⁻⁵ seq. buffer; 12 µl H₂O; 2 units T4 DNA ligase; 2 units DNA Polymerase I (Klenow fragment). The mixture was incubated for 16 h at 25°C.

The DNA was transformed in 1µl aliquots into *E. coli* strain BMH 71-18 mut L (Kramer *et al.*, 1984, Cell 38, 879-887). The transformed bacteria were plated onto a lawn formed from *E. coli* strain BMH 71-18. Some of the plaques resulting from the

transformations were picked and plated to form duplicate gridded arrays of bacterial colonies. These were lifted onto nitrocellulose and lysed as described (Grunstein and Hogness, 1975, P.N.A.S. 72, 3961).

Screening conditions: The nitrocellulose filters were prehybridised for 2h at 30°C in 6 × SSC (1 × SSC is 150mM NaCl, 15mM Na₂C₂H₃O₂·2H₂O) 0.1% SDS, 10 × Denhardt's (Denhardt's is 0.02% Polyvinyl-pyrrolidone, 0.02% Ficoll, 0.02% BSA), 50µg sonicated salmon sperm DNA. The filters were then mixed with a radioactively labelled oligonucleotide (a shortened version of the mutagenic primer, 5'-d(CCCTGGTACTTTTGAC) 3' under the same buffer conditions and were hybridised overnight at 30°C.

The filters were washed at a series of different temperatures in 6 × SSC plus 0.1% SDS: 3 × 5 minutes at 30°C; 5 minutes at 38°C; 5 minutes at 45°C; 5 minutes at 50°C; 5 minutes at 52.5°C; 5 minutes at 58°C. After each wash the filters were exposed, wet (with an intensifying screen) to Fuji RX-100 X-ray film.

Sequencing: DNA sequencing was carried out by the dideoxy termination method (Sanger, Nicklen and Coulson, 1977, P.N.A.S. 74, 5463).

Plasmid preparation: Large scale preparation of plasmid DNA and plasmid mini-preparations were carried out as described in Maniatis *et al.* - (Molecular Cloning -A Laboratory Manual, Cold Spring Harbor Laboratory, 1982).

Isolation of DNA fragments from low-melting-point - (LMP) agarose gels

DNA fragments were isolated from LMP agarose gels as described by Maniatis *et al.* - (Molecular Cloning, A Laboratory Manual, 1982, Cold Spring Harbor).

Ligation of Synthetic Linkers to DNA

Synthetic linkers encoding restriction enzyme sites, were kinased and ligated to blunt-ended DNA as described by Maniatis *et al.* (Molecular Cloning, A Laboratory Manual, 1982, Cold Spring Harbor).

Dephosphorylation of DNA

Vector DNA was dephosphorylated, where appropriate, by treatment with calf intestinal alkaline phosphatase as described by Maniatis *et al.* - (Molecular Cloning, A Laboratory Manual, 1982, Cold Spring Harbor).

Fibrin/agar overlay for detection of t-PA expression

Cell preparation: cells were trypsinised and plated out at 10^4 cells per 60mm dish and left overnight in growth medium (10% Serum, 1% stock solution of penicillin/streptomycin; Flow Laboratories, 1% Glutamine, 1% stock solution of non-essential amino acids; Flow Laboratories, in Eagles MEM) at 37°C in a humidified incubator in an atmosphere of 5% CO₂/95% air.

Transfection procedure: The transfection used - (calcium coprecipitation) is described in 'DNA Cloning' Ed. D.M. Glover (Chap. 15, C. Gorman). Glycerol shock and 10mM butyrate treatment were used. Following transfection the cells were rested overnight in growth medium.

Overlay: Agarose (Indubiose A₉), 2.4g in 95ml Eagles MEM (Gibco) heated to melting point in a bunsen flame, was then placed in a water bath maintained at 48°C. 5.6 ml of fibrinogen (20mg/ml) were diluted 1:1 with 5.6 ml of Eagles MEM (containing an extra 7 mg/ml of NaCl) and retained on ice. 3.3 ml of Eagles MEM (no additions) were aliquoted into a bijou containing 86μl of bovine thrombin at 50 NIH Units/ml (retained on ice). The cells were washed 3 times with Eagles MEM to remove serum. The thrombin and fibrinogen were warmed to 37°C in a water bath. 9.5 ml agarose were aliquoted into a pre-warmed universal. The thrombin was added to the agar, followed by the fibrinogen. The gel was poured over the cell layer and incubated at 37°C until lysis zones appeared.

Preparation of modified t-PA from bacterial extracts

Modified t-PA was extracted from cultures of *E. coli* JM101 (pTRB11) using a procedure based on that described by Heynecker *et al.* (1983) European Patent Application No. 0092182 for the extraction of active urokinase from *E. coli* cells. 10ml prewarmed L-broth (5g NaCl, 5g Yeast Extract, 10g Tryptone/litre of water) containing 50μg/ml ampicillin, were inoculated with 100μl of a standing overnight culture of *E. coli* JM101 (pTRB11) and incubated, with aeration, at 37°C until the A₆₀₀ = 0.5.

Expression of modified t-PA was then induced with 0.1mM IPTG (isopropyl β-D-thiogalactopyranoside) and ZnSO₄ was added to a final concentration of 0.5mM to minimise bacterial protease activity (Gross *et al.* Biochim. Biophys. Acta. 825, 207-213, 1985). Growth was continued for a further 2h (final A₆₀₀ = 1.0-1.2) and the cells placed in an ice bath. The cells were harvested, washed once with 1 volume ice-cold 10mM phosphate buffer pH 7.0 and the pellet resuspended in 1ml lysis buffer (50mM Tris pH 8.0, 50mM EDTA, 2mg/ml lysozyme). After 30 min at 0°C, 3 ml 8M guanidine HCl, 50mM Tris pH 8.0 were added and mixed

well. The cell debris was removed by centrifugation at 12,000g for 30 mins at 4°C and the supernatant decanted and incubated at 24°C for 30 mins. The solution was subsequently diluted to 1M guanidine HCl, 50mM Tris pH 9.0 and made 2mM reduced glutathione (GSH), 0.2mM oxidized glutathione (GSSG). This redox mixture was incubated at 14°C for 16h and then dialysed against 50mM Tris pH 9.5, 250mM NaCl, 0.25mM EDTA, 0.01% Tween for 8h (one change of buffer). 10μl of the dialysed extract were placed onto a fibrin plate (Robinson, J. Thrombos. Res. 1984; 33, 155-62) together with standards.

Example 2

Change in t-PA DNA sequence

DNA coding for a novel, modified t-PA protein has been produced using the above mentioned oligonucleotide (Example 1) with sequence:-

5' d(C G T G G C C C T G G T A C T T T T

G A C A G G C)3'

This oligonucleotide is complementary to nucleotides 327-339 inclusive and 451-462 inclusive of t-PA cDNA (Pennica *et al.* Nature, 1983, 301, 214-221). The 37 codons represented by nucleotides 340-450 are absent in this oligonucleotide and will result in a deletion of amino acids 51 to 87 inclusive in the t-PA cDNA. The resulting DNA sequence has been expressed in both prokaryotic and eukaryotic cell systems to give a novel fibrinolytically active protein.

All manipulation of the DNA referred to below was carried out as described in the Methods Section.

A cDNA clone coding for the protein t-PA was isolated from mRNA prepared from the TRBM6 cell line described in Thrombosis and Haemostasis, 1985, 54, 422-424. The 2kb BglII fragment encoding the mature t-PA cDNA sequence was isolated, blunt-ended and subcloned into M13 mp10 - (Amersham International PLC Prod. No. N.4536) at the Sall site which had also been blunt-ended. Clones were isolated with the insert in both orientations. The two types of clone will henceforth be known as mTR10 and mTR20. One of these, mTR20, placed the t-PA cDNA insert 'in frame' and in the correct orientation, to allow expression of a t-PA fusion protein from the lacZ promoter in the M13 mp10 genome (Siocombe *et al.* 1982, P.N.A.S. 79, 5455-5459).

This construct did not give good yields of either single or double stranded DNA.

Example 4

Transient Expression of modified t-PA DNA in Eukaryotic Cells

A. Vector Construction

The vector pRSV- β -globin (Gorman *et al.* Science, 221, 551-553, 1983) was modified to allow the insertion and expression of t-PA cDNA (see Fig.3). The β -globin sequences were removed by digesting 10 μ g of pRSV- β -globin DNA with 20 units each of HindIII and BglII for 2h and isolating the large DNA fragment from a 1% low melting point agarose gel as described in the methods section. The β -globin sequences were replaced with a DNA fragment encoding the 5' region of the cDNA from λ TR10 which is a λ gt10 cDNA clone - ('DNA Cloning, Vol.1, chapters 2 and 3, Ed. D.M. Glover, IRL Press, 1985) constructed using TRBM8 cell messenger RNA (Thrombosis and Haemostasis, 1985, 54, 422-424). The cDNA insert in the λ TR10 encodes the 5' untranslated region, prepro sequences and mature protein sequences up to the EcoRI site equivalent to base 801 (Pennica *et al.* Nature, 1983, 301, 214-221). The cDNA insert was cleaved from the vector by digestion of 5 μ g of DNA with 24 units of EcoRI for 1.5h. The DNA was then extracted with phenol/ chloroform, ethanol precipitated, resuspended, blunt-ended and ligated to kinased HindIII linkers as described in the Methods section. Ligation of linkers was at ambient temperature for 7 hours then overnight at 4°C. The DNA was then digested with 20 units of HindIII for 2 hours and a ~800bp fragment corresponding to the HindIII-linkered t-PA cDNA was isolated after electrophoresis in a 1% low melting point agarose gel. This ~800bp fragment was mixed with the large DNA fragment derived from pRSV- β -globin described above and ethanol precipitated. The DNA was resuspended and digested with 10 units each of HindIII and BglII for 1.7h, phenol/chloroform extracted, ethanol precipitated, resuspended and ligated as described in the methods section for 5h at ambient temperature and overnight at 4°C. 2 μ l of DNA was used to transform *E. coli* HB101 and colonies carrying plasmids containing the 5' end of the t-PA cDNA up to the BglII site equivalent to that numbered 187 in Pennica *et al.* (Nature, 1983, 301, 214-221), were identified by HindIII/BglII digestion of plasmid minipreps and the plasmid named pTRE1.

The sequences encoding the Rous sarcoma virus long terminal repeat (RSV-LTR), 5' region of t-PA cDNA, and Simian virus 40 (SV40) 3' sequences were then reconstructed in pAT153 in

such a way that they formed a single XhoI fragment. Firstly, the RSV LTR was removed from pRSV- β -globin by digestion of 6 μ g DNA with 40U of SfaNI for 2.5h. The DNA was then phenol/chloroform extracted, ethanol precipitated, resuspended and blunt-ended. XhoI linkers were kinased and ligated to the DNA at ambient temperature for 8h and overnight at 4°C, then incubated at 70°C for 15 minutes to inactivate the ligase and ethanol precipitated. The linkered DNA was then resuspended and digested with 15 units each of HindIII and XhoI for 8h and a ~500 bp fragment corresponding to the RSV-LTR isolated after electrophoresis in a 1% LMP agarose gel. This DNA fragment was cloned into pAT153 prepared as follows: 6 μ g of pAT153 was digested with 30U of EcoRI for 2h, then phenol/chloroform extracted and ethanol precipitated. The DNA was resuspended, blunt-ended, ligated to XhoI linkers, resuspended and digested with HindIII and XhoI as above. A ~3.4kb fragment was isolated after electrophoresis in a 1% LMP agarose gel and ethanol precipitated with the ~500bp fragment above. The DNA was ligated to give pTREO.

The ~0.2kb fragment encoding the 5' part of the t-PA cDNA was isolated from pTRE1 by digesting 10 μ g of DNA with 30 units each of HindIII and BglII for 2 hours and the fragment isolated after electrophoresis in a 1% LMP agarose gel. This fragment was cloned into pAT153 prepared as follows: 5 μ g of pAT153 was digested to completion with BamHI. Following phenol/chloroform extraction and ethanol precipitation, the DNA was resuspended and blunt-ended then ligated to kinased BglII linkers. The DNA was phenol/chloroform extracted, ethanol precipitated, resuspended and digested with 30 units each of HindIII and BglII for 3h. The large DNA band was isolated after electrophoresis in a 1% LMP agarose gel, ethanol precipitated with the ~0.2kb fragment above and ligated together to give pTREB.

A DNA fragment encoding the SV40 sequences from pTRE1 was isolated as follows: 5 μ g of pTRE1 was digested with 60 units of EcoRI for 2h, blunt-ended and ligated to XhoI linkers as described previously. After phenol/chloroform extraction and ethanol precipitation, the DNA was resuspended and digested sequentially with BglII and XhoI. A ~1.6kb band encoding the SV40 sequences was isolated after electrophoresis in a 1% LMP agarose gel and cloned into pTREB prepared as follows: 5 μ g of pTREB was digested with 15 units of Sall for 3 $\frac{1}{2}$ h, blunt-ended and ligated to XhoI linkers as described previously. Following phenol/chloroform extraction and ethanol precipitation, the DNA was resuspended and digested sequentially with 30 units of BglII for 1h and 10 units

XhoI for 2h. The large DNA band was isolated after electrophoresis in a 1% LMP agarose gel, ethanol precipitated with the ~1.6kb fragment above and ligated to give pTRE11.

A ~2kb DNA fragment encoding the 5' t-PA cDNA sequences, SV40 sequences and part of pAT153 were cleaved from pTRE11 by digestion of 5µg DNA with 30 units HindIII and 6 units XmaIII for 6h. After electrophoresis in a 1% LMP agarose gel a ~2kb band was isolated and cloned into pTREO prepared as follows: 4.8µg pTREO was digested with HindIII and XmaIII as above and the large DNA fragment isolated after electrophoresis in a 1% LMP agarose gel. This fragment was ethanol precipitated with the ~2kb fragment above and ligated to give pTRE12.

t-PA cDNA BglII fragments were cloned into the unique BglII site of pTRE12 as shown in Figure 4. pTRE7 contains a ~2kb BglII fragment, encoding the mature t-PA protein and part of the 3' untranslated region, derived from a cDNA library produced from TRBM6 cells, (Thrombosis and Haemostasis, 1985, 54, 422-424), cloned into the unique BglII site of pTRE1. 5µg of pTRE7 was


digested to completion with BglII and the ~2kb fragment isolated after electrophoresis in a 1% LMP agarose gel. This was ethanol precipitated and ligated with pTRE12, previously digested with BglII and phosphatased as described in the methods section, to give pTRE15 which expresses wild-type t-PA. mTR50 was digested with BglII and a ~1.9kb fragment isolated and cloned into pTRE12 as described above to give pTRE24 which expresses mutated t-PA.

B. Fibrin/agar overlay

Expression of modified and unmodified t-PA from transfected mouse C127 cells (24 hours post-transfection) was detected using the fibrin/agarose overlay technique as described in the Methods section. Lytic zones were obtained from pTRE15 - (unmodified t-PA) and pTRE24 (modified t-PA) transfected cells, but not from cells transfected with the empty parent vector pTRE12 (t-PA⁻).

In the figures:

Figure 1: Structure of bacterial expression plasmid pTRBII



The orientation of the t-PA encoding insert was determined by restriction with SmaI.

The expression plasmid carrying an unmodified t-PA insert, pTRB5, was constructed in a similar fashion.

Figure 2: Zymography of bacterial extracts

Activity was present in track II (modified t-PA DNA) and track III (unmodified t-PA DNA). For comparison, track I shows t-PA secreted from a eukaryotic cell.

Figure 3: Construction of vector (pTRE12) for insertion and expression of t-PA sequences

Abbreviations:

ATR10	-	λ gt10 clone containing the 5' part of t-PA cDNA
LTR	-	Rous sarcoma virus long terminal repeat
β	-	Rabbit β globin cDNA
SV	-	Simian virus 40 sequences including small t antigen intron and early region polyadenylation site
5'	-	5' part of t-PA cDNA (approximately 0.2kb long) with 3' end equivalent to the BglII site at position 187 in Pennica <u>et al</u> Nature <u>301</u> , 214-221, 1983
B	-	recognition site for BamHI
Bg	-	recognition site for BglII
E	-	recognition site for EcoRI
H	-	recognition site for HindIII
S	-	recognition site for SalI
Sf	-	recognition site for SfaNI
X	-	recognition site for XhoI
Xm	-	recognition site for XmaIII

Figure 4: Construction of vectors expressing wild-type or mutant t-PA (pTRE15 and pTRE24 respectively)

Abbreviations are as in Figure 3. t-PA wild type is cDNA encoding normal t-PA, t-PA mutant is cDNA encoding altered t-PA.

50

Claims

1. A fibrinolytically active tissue-type plasminogen activator which has been modified in the region of the growth factor domain.

55

2. A modified tissue-type plasminogen activator according to claim 1, which has been modified in the region from amino acid residues 51 to 87 inclusive.

3. A modified tissue-type plasminogen activator according to claim 1 or 2, wherein the modification comprises the deletion of all or part of the growth factor domain.

4. A modified tissue-type plasminogen activator prepared according to Example 3 or 4.

5. A derivative of the modified tissue-type plasminogen activator according to any of claims 1 to 4.

6. A DNA polymer comprising a nucleotide sequence that encodes a modified tissue-type plasminogen activator according to any of claims 1 to 4.

7. A replicable expression vector capable, in a host cell, of expressing a DNA polymer according to claim 6.

8. A host cell transformed with the vector according to claim 7.

9. An oligodeoxyribonucleotide comprising a nucleotide sequence which is complementary or corresponds to a region of the tissue-type plasminogen activator cDNA extending 5' from nucleotide 339 inclusive, said sequence being joined directly to a nucleotide sequence which is complementary or corresponds to a region extending 3' from nucleotide 451 inclusive of tissue-type plasminogen activator cDNA.

10. An oligodeoxyribonucleotide according to claim 9, wherein each said sequences has at least 12 nucleotides.

11. The oligodeoxyribonucleotide having the sequence (I):

5'd(CGTGGCCCTGGTACTTTTGACAGGC)3' (I)

12. A pharmaceutical composition comprising modified tissue-type plasminogen activator according to any of claims 1 to 5 in combination with a pharmaceutically acceptable carrier.

13. A modified tissue-type plasminogen activator according to any of claims 1 to 5 for use as an active therapeutic substance.

14. A modified tissue-type plasminogen activator according to any of claims 1 to 5 for use in the treatment of thrombotic disease.

15. A process for preparing modified tissue-type plasminogen activator according to claim 1, which process comprises expressing DNA encoding said modified tissue-type plasminogen activator in a recombinant host cell and recovering the modified tissue-type plasminogen activator product.

16. A process for preparing a DNA polymer according to claim 6, by the condensation of appropriate mono-, di or oligomeric nucleotide units.

17. A process according to claim 16, which process comprises effecting a site-directed or deletion mutagenesis upon the cDNA which codes for tissue-type plasminogen activator.

18. Modified tissue-type plasminogen activator obtainable by the process of claim 15.

19. t-PA A-chain which has been modified in the region of the growth factor domain.

20. A DNA polymer comprising a nucleotide sequence that encodes modified t-PA A-chain according to claim 19.

21. A hybrid protein comprising the modified t-PA A-chain according to claim 19 linked to the B-chain of a fibrinolytically active protease, the catalytic site of which is optionally blocked by a removable blocking group.

40

45

50

55

14




Fig.1





Fig.2







Fig.3b






Fig.4



DOCUMENTS CONSIDERED TO BE RELEVANT			EP 86302425.3
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to class	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
A	EP - A1 - 0 093 619 (GENENTECH) * Claims *	1, 6-8, 12-15, 18	C 12 N 15/00 C 12 N 9/68
D,A	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 81, no. 17, September 1984, Baltimore (Maryland, USA) T.NY et al. "The structure of the human tissue-type plasminogen activator gene: Correlation of intron and exon structures to functional and structural domains" pages 5355-5359 * Page 5358, column 1, line 31 - column 2, line 8 *	1-3	C 07 H 21/04 C 12 N 5/00 A 61 K 37/54 C 12 P 21/00
D,A	FEBS LETTERS, vol. 163, no. 1, October 1983, Amsterdam (N1) L. BANYAI et al. "Common evolutionary origin of the fibrin-binding structures of fibronectin and tissue-type plasminogen activator" pages 37-41 * Page 38, column 2, lines 9-16 *	1-3	TECHNICAL FIELDS SEARCHED (Int. Cl.4) C 12 N C 07 H A 61 K C 12 P
D,A	NATURE, vol. 301, no. 5896, January 20, 1983, New York (USA) D. PENNICA et al. "Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli" pages 214-221		
A	EP - A2 - 0 117 059 (GENENTECH)		
The present search report has been drawn up for all claims			
Place of search VIENNA		Date of completion of the search 11-07-1986	Examiner FARNIOK
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : member of the same patent family, corresponding document</p>			